Aetna Better Health of Maryland is not responsible or liable for content, accuracy or privacy practices of linked sites or for products or services described on these sites. If you did not intend to leave our site, click or tap the "x" in the upper right-hand corner.
Our decision-making process
Some medications on our formulary need prior authorization before they can be dispensed. First, you’ll request prior authorization for a member’s medication. Then, we’ll review your request and make our decision using the Maryland Department of Health’s prior authorization guidelines as well as our own custom guidelines.
Here are some of the guidelines we use in our decision making:
Non-formulary and prior authorization guidelines (PDF)
Cequa and Cyclosporine Ophthalmic Emulsion (PDF)
CGRP Injectable IV Infusion (PDF)
Compounded Drug Products (PDF)
Continuous Glucose Monitor (PDF)
Epogen - Procrit - Retacrit (PDF)
Epoprostenol-Flolan-Veletri (PDF)
Fentanyl - Oral and Intranasal (PDF)
Gender Affirming Care Services (PDF)
Icatibant - Sajazir - Firazyr (PDF)
Immune Globulin Intravenous (PDF)
Immune Globulin Subcutaneous (PDF)
Infliximab Remicade and Biosimilars (PDF)
Liraglutide, Ozempic, Trulicity (PDF)
Lupron Depot Endometriosis - Fibroids (PDF)
Lupron Depot Prostate Cancer (PDF)
Neulasta and pegfilgrastim (PDF)
Nitroglycerin 0.4 percent ointment (Rectiv) (PDF)
Proton Pump Inhibitor Post Limit (PDF)
Ranolazine Extended Release (PDF)
Sildenafil, Revatio, Liqrev (PDF)
Tadalafil (Cialis) for BPH (PDF)
Vyvgart - Vyvgart Hytrulo (PDF)
Zoledronic Acid - Reclast - Zometa (PDF)
Hepatitis C guidelines
Hepatitis C therapy prior authorization form (PDF)
You can find more information on the Maryland Department of Health’s website, including their:
- Hepatitis C clinical criteria
- Hepatitis C sample enhanced treatment plan
- Hepatitis C sample treatment plan
For more information
If you have questions or would like a copy of these guidelines sent to you, call Provider Relations at 1-866-827-2710 (TTY: 711).